Category: WFN1 Contributors

12318610 / 1859 POSTS
By John Vandermosten, CFANYSE:PLX READ THE FULL PLX RESEARCH REPORT Over the last few weeks, Protalix Biotherapeutics, Inc. (NYSE:PLX) has posted several updates includ-ing the announcement of pricing and closing of its ~$40 million financing. The co ...
How do you re-engage the customer who has gone dark on you? I share a tremendous amount of ideas and strategies in A Mind for Sales as to how to re-engage the customer that’s gone dark, but let’s walk through 10 things you can do in t ...
By David Bautz, PhDOTC:APLIF | TSX:APLI.TO READ THE FULL APLI.TO RESEARCH REPORT Business Update PRESECO Trial Interim Data in Late Calendar Q1/Early Q2 2021 On January 28, 2021, Appili Therapeutics, Inc. (OTC:APLIF) (TSX:APLI.TO) provided an update ...
By M. MarinNASDAQ:WINT READ THE FULL WINT RESEARCH REPORT Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently had positive updates on its assets and clinical programs, as the company advances drug candidate istaroxime and drug/device combination A ...
By M. MarinNASDAQ:KNDI READ THE FULL KNDI RESEARCH REPORT Kandi Technologies (NASDAQ:KNDI) is poised to benefit from the new U.S. administration’s goal to increase the government’s fleet of green energy vehicles, we believe. KNDI is one of the few EV ...
By Steven Ralston, CFA OTCQB:TGMGF | ASX:TGM READ THE FULL TGMGF RESEARCH REPORT Theta Gold Mines (OTCQB:TGMGF) (ASX:TGM) is a junior mining company on the cusp of becoming a gold producer by targeting high-grade, near-surface gold deposits in the b ...
By Steven Ralston, CFANYSE:VNRX READ THE FULL VNRX RESEARCH REPORT VolitionRx (NYSE:VNRX) is engaged in multiple epigenetic projects coupled with several corporate initiatives. The company is involved with developing numerous blood-based clinical ass ...
By Steven Ralston, CFANASDAQ:RKDA READ THE FULL RKDA RESEARCH REPORT Arcadia Biosciences (NASDAQ:RKDA) is on the cusp of increased revenue growth driven by the company’s GoodHemp and GoodWheat initiatives. Though the U.S. hemp effort has been delayed ...
If I were to ask you if you use Google Maps, I have a feeling you would say yes to using either that or using Siri/Alexa. (I better not say that, or it’s going to turn on.)We all have devices that provide directions for us and thank goodness. It ...
By John Vandermosten, CFANASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Initiation We are initiating coverage of MiMedx Group, Inc. (NASDAQ:MDXG) with a target price of $16.00 per share. This valuation is based on our estimates for continued growth ...
12318610 / 1859 POSTS